Tonix Pharma (TNXP) Stock Statistics & Valuation Metrics

Tonix Pharma has a market cap or net worth of $350.94M. The enterprise value is -$25.20M.

Tonix Pharma has 7,357,198 shares outstanding. The number of shares has decreased by -2.65% in one year.

Tonix Pharma’s return on equity (ROE) is -0.93 and return on invested capital (ROIC) is -52.17%.

The current PE Ratio of Tonix Pharma is ―. Tonix Pharma’s PEG ratio is ―.

In the last 12 months, Tonix Pharma had revenue of 10.09M and earned -130.04M in profits. Earnings per share was -3.50K.

In the last 12 months, operating cash flow was -38.83M and capital expenditures -193.00K, giving a free cash flow of -39.03M billion.

Tonix Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Tonix Pharma upcoming earnings date is Aug 11, 2025, TBA (Confirmed).

Tonix Pharma as a current ratio of 6.50, with Debt / Equity ratio of 0.31%

In the past 12 months, Tonix Pharma has paid -1.17M in taxes.

Tonix Pharma EV to EBITDA ratio is 0.21, with an EV/FCF ratio of 0.26.

Tonix Pharma has $131.72M in cash and marketable securities with $563.00K in debt, giving a net cash position of -$131.15M billion.

Gross margin is 29.81%, with operating margin of -770.20%, and net profit margin of -1288.25%.

The average price target for Tonix Pharma is $67.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy